C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the efficacy and safety of C-Trelin OD Tablet
5mg(Taltirelin Hydrate) in randomized, double-blind, placebo-controlled clinical trial in
patients with ataxia induced by spinocerebellar degeneration.
Phase:
Phase 4
Details
Lead Sponsor:
Chem Tech Research Incorporation HLB Pharmaceutical Co., Ltd.